Literature DB >> 1393273

Coeliac haemodynamic effects of endothelin-1, endothelin-3, proendothelin-1 [1-38] and proendothelin-3 [1-41] in conscious rats.

S M Gardiner1, P A Kemp, A M Compton, T Bennett.   

Abstract

1. Conscious, chronically-instrumented, Long Evans rats were given bolus doses of endothelin-1, endothelin-3 (both at 0.01 and 0.1 nmol kg-1), proendothelin-1 [1-38] and proendothelin-3 [1-41] (both 0.1 and 1 nmol kg-1) in order to compare their effects on coeliac haemodynamics, because it has been reported that, in conscious dogs, endothelin-1 has paradoxical, prolonged hyperaemic vasodilator effects in this vascular bed. Measurements were made also of mesenteric and hindquarters haemodynamics for comparison. In a separate experiment, endothelin-1 (0.1 nmol kg-1) was given before and 20 min after the onset of an infusion of mecamylamine (50 mumol kg h-1) to ensure that the responses measured were not confounded by rapid reflex changes in autonomic activity. 2. None of the peptides caused any increases in coeliac flow or any sustained rises in coeliac vascular conductance, although such changes were clear-cut in the hindquarters vascular bed following the higher dose of endothelin-1 and endothelin-3. In animals treated with mecamylamine the regional haemodynamic effects of the higher dose endothelin-1 were not different from those in animals with intact baroreflexes. 3. Although the lower dose of both endothelin-1 and endothelin-3 caused less marked coeliac, than mesenteric vasoconstriction, this difference was not apparent with the higher dose of the peptides, or with proendothelin-1 [1-38]. However, proendothelin-3 [1-41] had less marked coeliac and hindquarters vasoconstrictor effects than proendothelin-1 [1-38], in spite of both peptides causing similar changes in mesenteric haemodynamics.These differences could have been due to regional differences in the conversion of proendothelin-l [1-38] and proendothelin-3 [1-41] to endothelin-l and endothelin-3,respectively. Our findings contradict the proposition that exogenous proendothelin-3[1-41] is not converted into endothelin-3 in vivo.4. Since, in contrast to endothelin-1 and endothelin-3, proendothelin-1 [1-38] and proendothelin-3 [1-41] caused only small hindquarters vasodilatations, but large vasoconstrictions, it is feasible that the vasodilator responses to exogenous endothelin-l and endothelin-3 are pharmacological phenomena, and that, in vivo, the production of endothelins from proendothelins exerts widespread vasoconstrictor effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393273      PMCID: PMC1907517          DOI: 10.1111/j.1476-5381.1992.tb14360.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit.

Authors:  P D'Orléans-Juste; P S Lidbury; T D Warner; J R Vane
Journal:  Biochem Pharmacol       Date:  1990-05-01       Impact factor: 5.858

2.  Effects of indomethacin on the regional haemodynamic responses to low doses of endothelins and sarafotoxin.

Authors:  S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

3.  Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance.

Authors:  M Skolovsky; R Galron; Y Kloog; A Bdolah; F E Indig; S Blumberg; G Fleminger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1.

Authors:  Y Matsumura; K Hisaki; M Takaoka; S Morimoto
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

5.  Inhibition of biological actions of big endothelin-1 by phosphoramidon.

Authors:  T Fukuroda; K Noguchi; S Tsuchida; M Nishikibe; F Ikemoto; K Okada; M Yano
Journal:  Biochem Biophys Res Commun       Date:  1990-10-30       Impact factor: 3.575

6.  Differential effects of neuropeptides on coeliac and superior mesenteric blood flows in conscious rats.

Authors:  S M Gardiner; A M Compton; T Bennett
Journal:  Regul Pept       Date:  1990-07-30

7.  Regional hemodynamic effects of endothelin-1 in conscious, unrestrained, Wistar rats.

Authors:  S M Gardiner; A M Compton; T Bennett
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

8.  The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

9.  Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat.

Authors:  J R Haywood; R A Shaffer; C Fastenow; G D Fink; M J Brody
Journal:  Am J Physiol       Date:  1981-08

10.  Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo.

Authors:  T Kashiwabara; Y Inagaki; H Ohta; A Iwamatsu; M Nomizu; A Morita; K Nishikori
Journal:  FEBS Lett       Date:  1989-04-10       Impact factor: 4.124

View more
  5 in total

1.  Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan.

Authors:  G G Mattera; A Eglezos; A R Renzetti; J Mizrahi
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

2.  Regional haemodynamic responses to intravenous and intraarterial endothelin-1 and big endothelin-1 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

3.  Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

4.  The effect of Bosentan on healing of colonic anastomosis.

Authors:  Ziya Cetinkaya; Kazim Esen; Ibrahim Hanefi Ozercan; Bilal Ustundag; Refik Ayten; Erhan Aygen
Journal:  World J Emerg Surg       Date:  2006-12-18       Impact factor: 5.469

Review 5.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.